



US 20210363498A1

(19) **United States**

(12) **Patent Application Publication**
ZHAO et al.

(10) **Pub. No.: US 2021/0363498 A1**

(43) **Pub. Date: Nov. 25, 2021**

(54) **HIGH TITER RECOMBINANT AAV VECTOR
PRODUCTION IN ADHERENT AND
SUSPENSION CELLS**

(60) Provisional application No. 61/872,523, filed on Aug.
30, 2013.

(71) Applicant: **Amgen Inc.**, Thousand Oaks, CA (US)

Publication Classification

(72) Inventors: **Hui ren ZHAO**, Thousand Oaks, CA
(US); **Grace Ki Jeong LEE**, Simi
Valley, CA (US); **Thomas WOLFE**,
Carlsbad, CA (US); **Cherylene**
PLEWA, Burlington, MA (US); **Jackie**
Z. SHENG, Thousand Oaks, CA (US)

(51) **Int. Cl.**

C12N 7/00 (2006.01)

C12N 15/86 (2006.01)

(52) **U.S. Cl.**

CPC **C12N 7/00** (2013.01); **C12N 15/86**
(2013.01); **C12N 2750/14151** (2013.01); **C12N**
2750/14143 (2013.01); **C12N 2750/14152**
(2013.01)

(21) Appl. No.: **17/387,896**

(22) Filed: **Jul. 28, 2021**

(57)

ABSTRACT

Related U.S. Application Data

(63) Continuation of application No. 14/915,630, filed on
Feb. 29, 2016, now Pat. No. 11,078,464, filed as
application No. PCT/US2014/053281 on Aug. 28,
2014.

Disclosed are an in vitro method of producing a recombinant
AAV virion in a mammalian host cell that comprises a
functional adenoviral E1A gene (e.g., a HEK 293 cell) and
rAAV virions made by the method.

Specification includes a Sequence Listing.